Prelude Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Prelude Therapeutics Stock Summary

Prelude Therapeutics competes with Foghorn Therapeutics, Shattuck Labs, Monte Rosa, Kymera Therapeutics, and Nurix Therapeutics. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. Prelude Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 112 people.

Prelude Therapeutics Key Financial Ratios

Prelude Therapeutics Key Balance Sheet Accounts

Prelude Therapeutics Key Cash Accounts

Prelude Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Prelude Therapeutics's current stock value. Our valuation model uses many indicators to compare Prelude Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prelude Therapeutics competition to find correlations between indicators driving Prelude Therapeutics's intrinsic value. More Info.Prelude Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Prelude Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Prelude Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Prelude Therapeutics Systematic Risk

Today, most investors in Prelude Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Prelude Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Prelude Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Prelude Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Prelude Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Prelude Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Prelude Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Prelude Therapeutics's daily price indicators and compare them against related drivers.

When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.